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Inflammation of renal interstitium along with uvea involvement sets out the two 
components of tubulointerstitial nephritis and uveitis (TINU) syndrome. Though classically 
described as occurring in young females, it can affect a broad spectrum of patients.  
Both renal and eye disease could be asymptomatic and/or appear with an important delay. 
Renal disease gives rise to non-specific flu-like symptoms, often self-limited with 
therapeutic and with good prognosis. Eye-disease emerge mainly as a sudden-onset bilateral 
anterior uveitis and has a tendency for a chronic course, even under treatment. 
The syndrome was firstly thought to affect 2% of uveitis patients. Today, the challenging 
clinical features and the limited recognition are enlightened, and it is believed to be an under-
diagnosed illness. It is thus imperative to have a high clinical suspicion for TINU. 
We describe and analyze two clinical cases of TINU syndrome with different initial 
clinical manifestations and over one-year of follow-up. 
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RESUMO 
A inflamação do interstício renal, juntamente com o atingimento da úvea, estabelece os 
dois componentes da síndrome de nefrite tubulointersticial e uveíte (TINU). Embora 
classicamente descrita como ocorrendo em mulheres jovens, a síndrome pode afetar um 
amplo espectro de doentes. 
Tanto a doença renal como a ocular podem ser assintomáticas e/ou aparecer com um 
atraso importante. A doença renal dá origem a sintomas constitucionais inespecíficos 
semelhantes a uma síndrome gripal, muitas vezes autolimitados e com bom prognóstico. A 
doença ocular surge principalmente como uma uveíte anterior bilateral de início súbito e tem 
uma tendência para um curso crónico, mesmo sob tratamento. 
Os dados clássicos indicam que a síndrome afeta 2% dos doentes com uveíte. Atualmente, 
reconhecem-se as características clínicas complexas da doença, acreditando-se que seja sub-
diagnosticada. É, portanto, imperativo ter uma alta suspeita clínica para TINU. 
Neste trabalho são descritos e analisados dois casos clínicos da síndrome TINU com 
diferentes manifestações clínicas iniciais e com mais de um ano de acompanhamento. 
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I. DEFINITION AND EPIDEMIOLOGY 
In 1975 Dobrin et al. described for the first time the concomitant presentation of an acute 
idiopathic kidney inflammation accompanied by an anterior uveitis of unknown cause.1 
Today, around 300 cases of tubulointerstitial nephritis and uveitis (TINU) syndrome are 
reported in medical literature.2  
This syndrome has classically a female predominance and a median age of onset of 15 
years,3 with males having a likely earlier age of onset.3-4 However, this gender effect appears 
weaker than initially proposed and its occurrence in middle-aged people has also been 
reported.3,5–7 TINU syndrome has been described to occur in most ethnic groups, and no 
geographic nor racial predilection has to date been defined.  
Up to 2% of patients attending specialized uveitis centers are diagnosed with TINU,3,4,9 
and it accounts to nearly one-third (32%) of children and adolescents under 20 years-old 
with typical sudden-onset anterior uveitis.4 However, and as it will be later discussed, it is 
often deemed to be an under recognized disorder. 
 
II. RISK FACTORS 
TINU has been suggested to derive from the interplay of host vulnerability factors and 
environmental triggers. 
II.I.     FAMILY AND HLA 
The genetic predisposition of TINU is one of the most curious aspects of the disease and 
it is being highlighted, with clinical reports on monozygotic twins10,11, siblings12–14 and a 
mother and her son15 diagnosed years apart, without a likely common environmental 
influence. 
As with other autoimmune diseases, the investigation for genetic susceptibility markers 
has been centered on HLA genes. The human leukocyte antigens (HLA) system is the major 
histocompatibility complex (MHC) in humans. It consists of cell-surface proteins produced 
by genes located on chromosome 6 that are responsible for the regulation of the immune 
response. Specific HLA associations with TINU have lately been researched, the first one 
led by Mandeville et al. regarding the HLA-A2 and -A24 antigens in Japanese patients with 
TINU (75%).3 These were however subsequently identified as also common in healthy 
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Japanese subjects, and thus not relevant.7 Levinson et al. found in 2003 the link to HLA-
DQA1*01, HLA-DQB1*05, and HLA-DRB1*01. The strongest association was for the 
HLA-DRB*0102 allele (a subtype of HLA-DRB1*01), which was present in 72% (13/18) 
of  a TINU patients population, with an estimated relative risk (RR) of 167.116 that was 
further revised to 46.3.17 In this latter study, Mackensen et al. show that the HLA-DRB*0102 
allele occurs in increased frequency in one cohort of European patients with isolated sudden-
onset bilateral anterior uveitis (typical of TINU), but not in another group with isolated 
tubulointerstitial nephritis. This could provide evidence that these risk alleles might be most 
relevant for the uveitic component of TINU, particularly in younger patients.17 In the uveitis 
group was also described an association with HLA-DRB1*01 (RR = 4.0), which had not 
been shown in the earlier TINU cohort. 
In paediatric patients with panuveitis with or without known accompanying renal disease 
the frequency of TINU risk alleles (HLA-DRB1*01-HLADQB1*05 haplotype) was also 
reported to be higher (RR = 9.96) than in general North American population.14 A study 
conducted in a Finnish population with TINU did not show associations with the formerly 
described by Levinson “TINU susceptibility” alleles,18 perhaps because they are not 
common in Finland.5 Instead, this study revealed the association with the haplotypes 
DQA1*04:01 (RR = 4.0), DQA1*01:04 (RR = 6.1) and DRB1*14 (RR = 8.2) alleles.18  
Several other small studies and case reports referring association to the alleles cited above 
and even others have been published.5 The discrepancy between studies may reflect a 
regional variation in predisposing alleles. Hitherto, there is no determined susceptibility 
genotype across populations. 
II.II.    DRUGS AND INFECTIONS 
TINU appears to be an immune mediated process, in most cases idiopathic, that may be 
precipitated by drugs or infections.3,18,19 There is currently no well-established scientific 
evidence of a causal relationship between drugs or infections and TINU. Most studies in this 
field are retrospective, a substantial proportion of the suggested risk factors are common in 
the general population and may even coexist.5 
The most commonly associated infections originate in the respiratory tract.3 Prior 
infections with agents such as EBV,20–23 Chlamydia trachomatis,24 Mycoplasma 
tuberculosis,25,26 Toxoplasma gondii,27 and VZV reactivation28 have been related. 
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Non-steroidal anti-inflammatory (NSAIDs) agents and antibiotics are the main drug 
groups that have been involved,3,4,20 with other less well-known drugs, such as Chinese 
herbs,29 also reported. It is postulated that uveitis in TINU syndrome may be induced 
pharmacologically by pathogenic mechanisms distinct from the ones responsible for drug-
induced isolated uveitis, since they appear to have different causative agents.5,30 Likewise, 
the well-recognized NSAIDs-induced isolated tubulointerstitial nephritis (TIN) appears to 
be distinct from TINU, as it presents with heavy proteinuria and it has no apparent 
association with uveitis.31 
II.III.   OTHERS 
Autoimmune disorders such as rheumatoid arthritis, hyperthyroidism, parathyroidism and 
Sjögren syndrome have been implicated to follow TINU. It remains unclear whether these 
occurrences are merely coincidental or result of shared inappropriate immune responses.3 
 
III. PATHOGENESIS 
The exact immunopathology of TINU syndrome has so far not been clarified. The current 
proposal estimates that an environmental factor (such as drugs of infections) may trigger a 
autoimmune cascade in a susceptible genetic background. Both cellular and humoral 
immunity are thought to be involved in the disease development. 
Cellular immunity is believed to be a key-feature in the pathogenesis of TINU. HLA-
class II (such as HLA-RB1*0102) expressed on antigen-presenting cells is a crucial 
informant in the early phases of cellular immunity, presenting processed exogenous antigens 
to CD4+ helper T cells. It is therefore conceivable that a specific class II subtype might 
modify the immunity response to a pathogen, making a subject susceptible to a normally 
harmless antigen.17 Although none has as yet been discovered, a shared or similar antigen 
may explain the involvement of both organs.14 Furthermore, kidney analysis in TINU 
patients provides evidence of tubulointerstitial infiltrates composed primarily of 
helper/inducer T-cells subset,32–35 indicating that T-cell mediated immunity, in particular 
delayed-type hypersensitivity, could play a large role in this disorder.36 FOXP3+ T 
regulatory lymphocytes are central to the maintenance of self-tolerance and tissue 
homeostasis by suppressing pathological and physiological immune responses.37 Its 
quantitative and/or functional impairment results in a diminished ability to suppress effector 
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T cell proliferation and has been implicated in many autoimmune diseases and malignancies. 
These cells have been recently found in kidney biopsies samples from paediatric TINU and 
TIN patients.38 When compared to patients with isolated TIN or TINU with uveitis lasting 
<3 months, CD4+ and/or FOXP3+ T-cells have been shown to be present in a smaller 
amount in patients with TINU with chronic uveitis. This may indicate a different 
pathogenesis for these conditions. T-reg activation may thus be restrained in TINU patients 
with chronic uveitis, leading to a persistent inflammatory response and to the chronicity of 
the clinical condition.38 
The role of humoral immunity was firstly suggested by the identification of autoreactive 
antibodies in patients with TINU syndrome against a 125-kD antigen in both renal and uveal 
cells.32,39 Tan et al. have shown later the presence of autoantibodies against modified C-
reactive protein (mCRP), a dissociated monomer of the acute phase reactant pentamer (C-
reactive protein), in renal and ocular tissue of TINU patients.40 In comparison with other 
renal autoimmune diseases and normal controls, they noted a significantly higher prevalence 
of serum anti-mCRP autoantibodies in TINU syndrome, especially in the active phase of 
nephritis. These results suggest that anti-mCRP may be one of the common target 
autoantigens in both tissues, having disease-specific relevance.40 However, it has not been 
proved whether this autoantibodies are pathogenic in this disease, since they could merely 
arise from a chronic inflammation with formation of acute phase reactants, as documented 
in lupus nephritis.41 Moreover, it has been defined that in patients with acute interstitial 
nephritis, elevated anti-mCRP antibodies were predictive of subsequent uveitis 
development.42 This is in line with the clinical evidence suggesting that the kidney may be 
the primary target of a sequential process, possibly leading to an inflammatory cascade with 
secondary effects on the eye. Regarding the humoral immunity, it is also to note the 
recurrence of TINU in a patient following a kidney transplantation, suggesting that the target 
renal antigen might be a wild-type endogenous protein.43 
 
IV. CLINIC 
The renal and ocular symptoms have often an asynchronous presentation.44 In most cases 
(65%), the uveitis follows the interstitial nephritis with an average delay of 3 months, 
although up to 14 months has been noted. In 20% of patients, the eye disease can also precede 
the kidney illness and, in a minority (15%), they both have a concurrent onset.3,45 
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IV.I.    RENAL DISEASE: SYMPTOMS AND SIGNS 
Tubulointerstitial nephritis is a frequent cause of acute kidney injury (AKI) and a 
potentially life-threatening condition. It is characterised by an immune-mediated infiltration 
of the kidney interstitium by inflammatory cells. In TINU syndrome, renal involvement is 
generally mild, resolving sometimes spontaneously, and there is a correlation between the 
patient’s advanced age and the severity of renal disease.3,45  
Patients may be asymptomatic or present with prolonged non-specific constitutional 
symptoms, classically associated with a hypersensitivity reaction, which can be mistaken for 
a “flu-like syndrome”. These include weight loss, malaise, fever, rash, arthralgia or 
abdominal/flank tenderness/pain. Among them, fever is the most frequent and less than 10% 
develop the classic triad of fever together with rash and arthralgia.45,46 Polyuria and nocturia 
have also been reported in up to 8% of cases.3,45  
IV.II.   OCULAR DISEASE: SYMPTOMS AND SIGNS 
Non-infectious uveitis accounts for one of the main causes of preventable, irreversible 
vision loss. 47 TINU’s uveitis develops between 2 months prior to 12 months after the onset 
of TIN,3 but the ocular symptoms are also not always present.4,49 Asymptomatic uveitis in 
TINU syndrome may be under recognized, with prospective studies identifying it in up to 
50% of the patients. 2,50 This may be especially important in young children, in which uveitis 
frequently causes few or no symptoms. Even in more severe cases, parents may not be aware 
of any visual impairment until the development of severe complications. 47 
Unlike other inflammatory eye diseases, the TINU-related uveitis is often 
symptomatic.47,51 Most patients experience a bilateral sudden-onset non-granulomatous 
anterior uveitis, presenting with typical symptoms of redness, pain and photophobia. Ocular 
manifestations are described as bilateral in about 80% of cases.52 The uveitis is initially 
located in one eye, with the median time for second-eye involvement being one week.4 
Posterior uveitis or panuveitis can also be part of the clinical picture, occurring in up to 20% 
of patients, although it is thought to be underappreciated as a manifestation of TINU.2,3 There 
are also a few reports of confirmed TINU with granulomatous anterior uveitis.53,54 
Other symptoms that may also arise are eyelid oedema and rapidly progressive loss of 
vision. Signs include presence of conjunctival and perilimbal injection, small pupils with 
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sluggish or no light reaction.55 Nodular scleritis may be part of the possible spectrum of 
ocular inflammation. 56 
Considering the relative broad spectrum of eye manifestations, examination of both the 
vitreous and fundus should be an integral part of ophthalmologic examination. Slit-lamp 
examination reveals anterior chamber cells and flare, fine keratic precipitates and vitreous 
cells. Recurring and/or prolonged inflammatory cases can be accompanied by mutton-fat 
keratic precipitates (granulomatous inflammation), fibrin deposition, anterior (iridocorneal) 
or posterior (iridolenticular) synechiae and hypopyon.6,57 Although not typically affected, 
posterior involvement manifestations comprise intraretinal haemorrhages or retinal vascular 
sheathing, cotton wool spots, dilated retinal vessels, disk and macular oedema, focal and 
multifocal choroiditis and choroidal neovascularization.55,58- 60 
 
V. DIAGNOSTIC 
TINU syndrome remains a diagnosis of exclusion. Other disease entities known to cause 
both of these disorders must first be excluded.3,22 TINU is usually diagnosed in either of two 
initial contexts: an azotaemia of unknown origin, conceivably related to a flu-like illness, or 
a spectrum of ophthalmologic symptoms, namely visual impairment, burning and/or red 
eyes.31 This diagnostic should be promptly suspected in young patients presenting with either 
uveitis or tubulointerstitial nephritis. After the suspicion, definite diagnostic is only 
confirmed through renal histopathology. 
V.I.      LABORATORY EVALUATIONS 
The classic triad of TINU consists of nephritis and uveitis together with an inflammatory 
syndrome that may lead to peripheral blood abnormalities, such as normochromic, 
normocytic anaemia, elevated erythrocyte sedimentation rate, hypergammaglobulinaemia 
and elevated CRP.61 An inconsistent feature is the development of peripheral blood 
eosinophilia.5 
The renal disease (tubulointerstitial nephritis) is difficult to diagnose based on clinical 
examination alone. As result of tenuous clinical manifestations, the diagnostic of TIN may 
be challenging and sometimes only achieved through abnormal laboratory findings. Unlike 
the classic drug-related TIN, the renal disease in TINU’s syndrome usually lack a well-
defined triggering event, and there are no specific cutaneous, hematologic or urinary 
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correlates.31 In patients with unexplained acute kidney injury (elevated blood urea nitrogen 
and/or creatinine) or progressive reduction in glomerular filtration rate (GFR), TIN should 
be suspected.5 An hyperkalemic, hyperchloremic metabolic acidosis out of proportion to the 
renal dysfunction can occur.46 
TIN affects primarily the renal interstitium and the tubular wall without prominent 
glomerular or vascular involvement.34 Urinalysis abnormalities reflect this, yet the findings 
are usually nonspecific. Microscopic examination of the urinary sediment may be bland or 
denoted by sub-nephrotic proteinuria, microscopic haematuria, sterile pyuria and 
aminoaciduria.3,39 Because glomerular pathology is not significant, high albuminuria levels 
are usually not seen, but tubular proteinuria may be detectable.5 Although not evaluated in 
routine laboratory tests, urinary eosinophilia may also be observable.5 Evidence of proximal 
tubular dysfunction is common, such as normoglycemic glycosuria and Fanconi syndrome 
(glycosuria, aminoaciduria, acidosis).3,31,45 
Biomarkers of kidney tubular damage, such as urinary N-acetylglucosaminidase (NAG) 
and β2-Microglobulin (B2M) are helpful suggesting the diagnostic and are commonly found 
in TINU. B2M is a small globular protein filtered at the glomerulus and reabsorbed at the 
proximal tubule, representing a very sensitive marker for tubular damage.4 In patients with 
uveitis, the positive predictive value of increased serum creatinine and urinary B2M levels 
has been reported to be 100% and the negative predictive value of 97% for detecting 
associated TIN.52 Urinary B2M levels have therefore been proposed as a screening measure 
for patients with uveitis, to help on assessment of TINU syndrome.4  A correlation between 
urinary B2M levels and the histologic grade of TIN in 10 paediatric patients has been shown. 
34 
Despite this, it is noteworthy that there is also evidence of subclinical forms of biopsy-
confirmed TINU syndrome in Japanese patients with normal renal function.8 Endocrine 
abnormalities of the thyroid and parathyroid glands could be associated. Therefore, thyroid 
stimulating hormone testing is recommended in newly diagnosed patients.61 
V.II.    KIDNEY BIOPSY 
The typical histopathological findings on renal biopsy are the only way of proving the 
definitive diagnostic of tubulointerstitial nephritis (TIN), and thus TINU syndrome.8,50,62 
TIN is characterised histologically by interstitial oedema with infiltration of inflammatory 
cell (predominantly T lymphocytes along with neutrophils and plasmatocytes) and tubular 
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damage with tubule oedema, epithelial degeneration and focal necrosis. Granuloma 
formation is uncommon. Conversely, the normal structure of glomerular matrix, blood 
vessels and the number of mesangial cells is preserved.6,63 
Nonetheless, it should be noted that TIN remains a clinical diagnosis, with suggestive 
clinical signs, such as low-molecular-weight (LMW) proteinuria (elevated α1 or β2-
Microglobulin). As an invasive procedure, kidney biopsy causes discomfort and pain, and 
may not be suitable for all the patients. In patients suspected of having TINU syndrome with 
normal serum renal parameters, the biopsy is not recommended. It should be appraised on 
individual basis and considered with uncommon features of TIN, unidentifiable offending 
agent, severe renal dysfunction, renal disease relapse, or prior to starting treatment.55,8,64  
V.III.   FLUORESCEIN ANGIOGRAPHY 
Fluorescein angiography is valuable in assessing the extent of retinal involvement, since 
the retina may be involved without any apparent manifestations on funduscopic examination. 
A common finding is the leakage of fluorescent dye from the optic disks and central-to-
peripheral microvessels, on degrees ranging from limited to the peripheral fundus to cystoid 
macular oedema. Retinal capillary leakage is consistent with blood-retina barrier 
disruption.6,39,59  
V.IV.   HLA TYPING 
Renal symptomatology is often a cause of late referral to specialized centres. HLA-
DRB1*0102 allele might provide a time-independent marker, useful to suggest the diagnosis 
of TINU. Therefore, HLA-DR, DQ class II DNA typing may help narrowing the differential 
diagnosis and defining a need for further medical assessment in both typical TINU’s uveitis 
and in some atypical cases, such as paediatric patients with panuveitis.14,17 This may be 
particularly important in patients without evident renal disease, where the alleles detection 
could target the patients who would require additional evaluation of renal function. The 
sensitivity and specificity of this test seem to be relative good in North American and 
European patients.14   
V.V.     DIFFERENTIAL DIAGNOSTIC 
Ocular and renal inflammation overlap can occur in other systemic illnesses, notably 
sarcoidosis, Sjögren’s syndrome, systemic lupus erythematosus (SLE), granulomatous 
polyangiitis, Behçet’s disease, tuberculosis (TB) and syphilis.3,5,65 The typical uveitis 
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subtypes, median age of onset, and other characteristic systemic symptoms and signs can be 
promptly distinguishable. A complete review of systems and clinical examination should 
guide the serologic and imagiologic testing for these conditions.55,65 
Sarcoidosis can be particularly similar to TINU’s syndrome, with Ali et al. even 
hypothesizing about a common pathogenesis.66 The distinction may be particularly 
challenging in the paediatric population where the typical pulmonary manifestations may 
not arise.65 Sarcoidosis is typically a prolonged systemic granulomatous disease, where eye 
and kidney can be affected. The eye is commonly implicated, presenting with acute anterior 
bilateral uveitis or panuveitis with chorioretinal lesions. Kidney involvement is less frequent, 
with 20% having granulomatous interstitial nephritis, with elevated urinary B2-
microglobulin levels.54,67,68 Granulomas are the exception in TINU disease. Nevertheless, 
the syndrome can have an associated granulomatous disease, with reports of granulomas in 
the eye, bone marrow and liver. In challenging cases, such as in granulomatous uveitis 
(suggestive of sarcoidosis), a renal biopsy may clarify the diagnosis, as the granulomas are 
rare in patients with isolated interstitial nephritis, including TINU. However, there are 
sometimes grey areas where even the histological findings do not confirm a diagnosis. It is 
thus important to keep in mind that TINU is a diagnostic of exclusion. 3,46,65 
V.VI.   CRITERIA AND PROBLEMS IN DIAGNOSIS 
Mandeville and associates described in 2001 the evaluation criteria for TINU syndrome. 
Alongside the typical uveitis, clinical diagnosis was based on three components as follows: 
1. Abnormal serum renal function (increased serum creatinine or decreased creatinine 
clearance); 2. Abnormal urinalysis: increased β2-Microglobulin, low-grade proteinuria, 
presence of urinary eosinophils, pyuria or haematuria without infection, urinary white cell 
casts, or normoglycemic glycosuria; and 3. A systemic illness lasting ≥2 weeks, 
characterized by a combination of the following symptoms and laboratory findings: (a) Signs 
and symptoms: fever, weight loss, anorexia, malaise, fatigue, rash, abdominal or flank pain, 
arthralgia, or myalgia; and (b) Laboratory findings such as the evidence of anaemia, 
abnormal liver function, eosinophilia, or a erythrocyte sedimentation rate >40 mm/h.3 
TINU is thought to be an under recognized syndrome due to a combination of absence 
and/or asynchronicity of the ocular and renal symptomatology. This might be particularly 
important in paediatric population. More frequently, renal symptoms arise first, and kidney 
function tests may be altered before the ocular inflammation, which can be difficult to 
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diagnose and treat in the early stages. The subsequent uveitis may cause few or no symptoms 
and, when arising, may be late in onset and the link with the renal disease may be missed. 
The ‘idiopathic’ tubulointerstitial nephritis diagnostic may thus be incorrectly established. 
TINU syndrome is thought to be a rare cause of ATIN.39 The highest prevalence of uveitis 
related with TIN in a retrospective case study was 46%, reaching 84% in a prospective study 
conducted in the same population submitted to regular slit-lamp examination, and may be 
higher with longer follow-up time, due to late-onset presentation of ocular 
inflammation.2,18,19,50  
On the other hand, mild renal disease may be hard to detect, since it can exhibit 
nonspecific symptoms or may not become symptomatic. Diagnostic tests regarding renal 
involvement are therefore either not obtained or not performed at the time of presentation of 
uveitis.3,58 Even when assessed, renal investigations may already be normalized, given the 
self-limiting nature of the kidney disease. This naturally delays or hinders the diagnosis of 
TINU and it is responsible for cases labelled as ‘idiopathic’ uveitis. Even when both diseases 
cause symptoms, they may not be synchronous, and the connection between them may be 
missed.5  
 
VI. TREATMENT AND PROGNOSTIC 
Long-term follow-up of TINU’s syndrome is to date still insufficiently studied. The long-
term outcomes with treatment are generally good for both eye and kidney, but TIN and 
uveitis have been thought to have independent courses and severities.3,48,55,69,70 As a rare 
disease, its treatment is not standardized. During the active phase, both ocular inflammation 
and renal function respond readily to corticosteroid treatment, but the eye-disease control 
can be more challenging. The uveitis has been reported to persist or relapse even after 10 
years, whereas the renal disease is often self-limited.4,44,71 
Topical corticosteroids and cycloplegic agents are the first-line treatment for anterior 
uveitis. However, in the acute phase of TINU’s anterior uveitis, up to 80% of patients will 
require systemic corticotherapy. 3,54 In other uveitis subtypes, systemic steroid therapy is the 
preferential initial treatment. 3,54,65 Earlier short-follow publications reported high rates of 
spontaneous resolution with corticosteroids, with only 10% of refractory patients. 3 More 
recently it has been shown that in 70% of TINU patients systemic steroid therapy does not 
seem to be sufficient to prevent recurrences of uveitis. 54,55 
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Younger age has been identified as a risk factor for developing chronic uveitis lasting >3 
months. Ocular inflammation recurs in up to 50% of patients after corticosteroid withdrawal 
and relapses are generally often more severe than the initial event.3,34,54,71 
Immunomodulation therapy (IMT) drugs are the second-line treatment, including 
methotrexate, cyclosporine, azathioprine or mycophenolate mofetil. 22 In the series of 
Sobolewska et. al, it has been shown that, with adequate prolonged IMT treatment, the 
control of the ocular disease may be achieved with improved recurrence-free period.22,54 
They reported a median treatment duration of 29.5 months (range: 13-40 months) in most 
patients (70% (6/9)) over a follow-up period of 4.5 years (range: 24-133 months).54 IMT 
therapy could be therefore considered in steroid-resistant cases or to lessen undesirable 
steroid-related adverse effects. This treatment should seek to maintain quiescence for at least 
12-24 months before withdrawal.65 
Despite the difficult control, TINU’s uveitis carries a good prognosis for visual acuity, 
with an average vision of 20/25, that rarely decreases below 20/40. 2,4 Ocular complications 
occur in 20% and include posterior synechiae (the most common), optic disc oedema, cystoid 
macular oedema, cataracts, elevated intraocular pressure or chorioretinal scarring. 3,4,8,54,55 
Some complications are strongly associated with systemic and topical corticosteroids, 
particularly cataracts and elevated intraocular pressure. 14,55 
Most TINU patients are treated with systemic therapies for the renal disease, even in the 
absence of ocular indication. Earlier studies suggested that renal disease in TINU is self-
limiting, spontaneously or after steroid treatment, with persistent renal dysfunction only in 
about 10% of patients.44 Later there have been reports in the development of end-stage renal 
failure in patients with TIN not treated with systemic steroid therapy,72 and histological 
changes of acute kidney inflammation in biopsy-samples despite systemic prednisone 
treatment, even 6-9 months after the diagnosis of TINU.33,73 Even minimal tissue damages 
might lead to chronic kidney disease and hypertension,17 and although unusual, severe TINU 
may lead to chronic dialysis and kidney transplantation.3,4,70 Moreover, it should be stressed 
that systemic corticosteroids for treatment of TIN do not seem to prevent or reduce the 
occurrence of later uveitis. 2,74,75 
Management of TINU has not yet been sufficiently researched, due to the rarity of this 
disorder and variabilities regarding primary endpoints and patient age group.65 The course 
and severity of both the nephritis and uveitis and their treatment should be managed by 
ophthalmologist together with nephrologists. Because the tubular dysfunction may persist 
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regardless of treatment, it is recommended during the follow-up of renal disease urinalysis 
and quantitation of LMW protein excretion even in patients with normal serum creatinine 
concentration. 2 
Considering that the uveitis symptoms may be inconspicuous and delayed in onset, 
ophthalmologic screening is warranted for all patients with isolated TIN for at least 1 year 
after the diagnosis, starting with 3-month intervals.2,50 On the other hand, in patients with 
typical TINU’s bilateral sudden-onset anterior uveitis, renal disease should also be ruled out. 
Although the transient renal findings may already be normalized, urinary B2M levels and 
serum creatinine have been proposed as a screening measure, with positive and negative 
predictive values of 100% and 97%, respectively.4,52 This is particularly important when a 
renal biopsy is not indicated. 2,3,52 
 
VII. CASE REPORTS 
VII.I.    CASE 1 
A 18-year-old previously healthy woman sought medical assistance for general malaise 
with tiredness, nausea, vomiting and weight loss lasting for several weeks. Blood tests were 
normal despite elevated serum creatinine (2.8 mg/dL) and erythrocyte sedimentation rate (90 
mm/h), and she was admitted for medical management. The urinalysis showed a proteinuria 
of 400 mg/24h without urinary eosinophils. Her medical history was unremarkable, and as 
regular medications, she was taking ibuprofen due to intense dysmenorrhea during her 
menstrual periods. Clinical assessment did not reveal signs of recent infection, skin rash, 
arthralgia, arthritis, muscular pain, photosensitivity or alopecia. Viral serologies, 
antistreptolysin O test, and further autoimmunity tests were all negative. Angiotensin-
converting enzyme (ACE) levels were normal. During the hospitalisation, urine output 
remained stable, with progressive improvement of renal function. Kidney echographic 
findings were normal, and chest-abdominal-pelvic computed tomography was 
unremarkable, with no visible mediastinal lymph nodes. At the time of medical discharge, 
the kidney function showed creatinine level of 1.8 mg/dL and BUN of 45 mg/dL. 
One month later, the patient experienced right red painful eye and reduced visual acuity, 
and acute anterior uveitis was identified. Kidney biopsy could confirm the tubulointerstitial 
nephritis, and TINU diagnostic was established. The patient was treated with oral 
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prednisone. Upon adequate clinical response and normalisation of kidney function after 1 
month of treatment, steroids were slowly tapered off, with a rapid recurrence of the ocular 
inflammation. Without systemic therapy, the patient had recurrent bilateral acute anterior 
uveitis, treated with intensive topical steroids and cycloplegia. Due to the uveitis relapse 
with difficult control of the eye disease, the institution of systemic therapy was discussed 
with nephrology colleagues and treatment with oral methotrexate was started up to a dose of 
17.5 mg/week. After one year of surveillance for eye and kidney disease and acceptable 
treatment tolerability, the patient remains asymptomatic with no signs of active 
inflammation.  
VII.I.    CASE 2 
A 12-year-old girl presented in emergency department for right eye redness and 
photophobia. On the slit-lamp examination, fine keratic precipitates and posterior synechiae 
were observed. The fundus assessment did not disclose any abnormality. Right acute anterior 
non-granulomatous uveitis was diagnosed, and the patient was treated with topical 
prednisolone and cyclopentolate. The physical examination was normal, with no signs of 
recent infection, nor signs of joint swelling, joint stiffness or gastrointestinal symptoms. She 
had started oral contraceptives 5 months before and reported fatigue and anorexia in the past 
month. 
In routine a medical check-up 1 month before, the blood tests showed a normocytic 
normochromic anaemia (Hb 11.3, MCV 83, MCH 27.6) with low serum iron (32 µg/dL), 
normal creatinine levels (1.18 mg/dL), with thyroid function and further laboratory 
assessment unremarkable. She was then medicated with iron supplementation. After one 
week of topical treatment, the patient experienced a worsening of the uveitis, with bilateral 
involvement. A new blood panel reveals hypergammaglobulinemia, increase in creatinine 
concentration (1.38 mg/dL), with normal BUN, C-reactive protein 0.3 mg/dL, and normal 
liver enzymes. ACE level was normal. Antinuclear antibodies were negative. Serologies for 
HIV, hepatitis and syphilis were also negative. Urinalysis revealed proteinuria, glycosuria, 
leukocyturia, haematuria, and high levels of urinary B2M (12.51 mg/dL). Both eye and 
kidney involvements were identified clinically, and TINU syndrome was thus diagnosed. 
The renal histopathological findings confirmed this diagnostic. Because of incomplete 
response to topical treatment, systemic treatment with prednisone 20 mg/day was initiated 
and later due to incomplete response to oral steroids, methotrexate up to 17.5 mg/week was 
started, with excellent response and quiescence of ocular involvement. . At the end of the 
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second month, laboratory findings were normal, the patient was asymptomatic, and the 
systemic steroids could be gradually tapered off. The patient remains under over 10 months 
of methotrexate treatment with no further complications. 
 
VIII. DISCUSSION 
We observed two cases of TINU with different initial clinical presentations. Regarding 
gender and the age of the patients, both are in line with the classical epidemiological features 
of the syndrome.  
The nonspecific symptoms typical of renal involvement appeared firstly in both cases, 
though with different manifestations and intensities. Constitutional flu-like symptoms were 
the initial motive for referral in the first case. The delay between the occurrence of renal and 
eye symptoms was of 2 months and 1 month in the first and second case, respectively. As 
described in the literature, also both of our patients experienced a first episode of unilateral 
acute anterior uveitis, the second-eye being rapidly involved with the persistence of the 
inflammation. 
The diagnostic establishment was challenging in both cases. In the first one, the general 
nonspecific manifestations together with the urinalysis alterations could point towards an 
idiopathic tubulointerstitial nephritis, since no triggering infective agent could be identified, 
and the patient had no known genetic nor systemic inflammatory conditions associated. The 
eye involvement developed subsequently with the typical bilateral acute anterior uveitis, and 
a kidney biopsy could finally confirm TINU. The second patient presented with an episode 
of a non-infectious right acute anterior uveitis with no identifiable cause. Given the recent 
initiation of a contraceptive treatment, a drug-related uveitis could be a possibility. 
Nonetheless, this remains a diagnosis of exclusion, since a link is not possible to ascertain. 
The general symptoms were initially related the microcytic hypochromic anaemia on 
treatment, with no evident connection with the uveitis. TIN-related systemic symptoms were 
therefore not pronounced, and recognition of kidney involvement was only possible in view 
of the laboratory abnormalities, with the typical high concentrations of creatinine and B2M. 
TINU diagnosis was confirmed in a kidney biopsy. Sarcoidosis was an important differential 
diagnosis in both patients, but absence of granulomas and normal ACE levels could rule out 
this disorder.  
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With regards to treatment, in the first case one month of systemic steroids could control 
eye and kidney involvement. On therapy discontinuation, uveitis relapses are more severe 
than the initial condition and with difficult management under topical-steroids alone. 
Methotrexate was introduced, and disease control is accomplished for one year of follow-
up. In case 2, the approach to treatment was different. To the initial isolated anterior uveitis 
topical steroids are administered, without success. Persistent uveitis justified further 
assessment and TINU syndrome was diagnosed. Systemic steroids plus methotrexate were 
instituted, and after two-month steroid treatment could be tapered. Treatment with 
methotrexate allow control of the disease for over 10 months. 
In both cases, the progression of the syndrome was typical with the reported previously 
in several studies. Whereas the renal disease had a rapid regression under steroid systemic 
therapy, the progression of uveitis lead to the need for treatment extension with IMT. 
Analysing the two different treatment options, for the same duration of systemic therapy 
(i.e., one month), the relapsed uveitis was easier to manage in the case where combined-
therapy with corticosteroids and methotrexate was started early in the treatment course. 




Our cases reflect the wide range of presenting symptoms that TINU patients may undergo 
and highlight the complexity of this diagnosis. Both patients presented with typical eye-
kidney disease courses and the treatment response was similar to the formerly reported in 
the literature and detailed in this review. It is important to bear in mind the under-recognition 
of TINU syndrome, as its prevalence and importance might be much higher than initially 
thought. A high-grade clinical suspicion is crucial, with important attention to the cases 
“labelled” as idiopathic tubulointerstitial nephritis or idiopathic uveitis. These patients 
should be surveilled to the occurrence of subsequential eye or renal disease, respectively.  
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X. RESUMO  
A Síndrome TINU (Nefrite Tubulointersticial e Uveíte) foi descrita primeiramente em 
1975 e descreve o atingimento inflamatório do olho e do rim.  
Classicamente, destacou-se na epidemiologia uma predominância feminina, com os 
primeiros sintomas a surgir numa média de idade de 15 anos. Apesar disto, hoje sabe-se que 
esta síndrome pode ocorrer em ambos os sexos, e pode atingir qualquer idade, sem apresentar 
especial predileção ética, geográfica ou racial. O diagnóstico de TINU é determinado em 
cerca de 2% dos doentes que recorrem a centros especializados de uveíte, e esta doença é 
responsável por até um terço das crianças e adolescentes com idade inferior a 20 anos com 
a típica uveíte anterior de início súbito. 
Como fatores de risco destacam-se, por um lado, a suscetibilidade genética e, por outro, 
agentes externos.  A predisposição genética é um dos aspetos mais interessantes da doença, 
estando reportados casos em gémeos homozigóticos, irmãos e numa mãe e no seu filho. A 
investigação de marcadores genéticos de suscetibilidade tem-se centrado nos genes do 
complexo HLA, destacando-se os HLA-DQA1*01, HLA-DQB1*05 e HLA-DRB1*01. A 
associação mais forte foi com o alelo HLA-DRB*0102, que se mostrou presente em 72% 
(13/18) de uma população de doentes com TINU. Outros estudos com amostras menores 
revelaram associações para os alelos supra-mencionados e ainda outros, havendo uma 
discrepância entre estudos que poderá ser justificada por uma variação regional nos alelos 
predisponentes. Os fármacos e infeções poderão ter um papel importante, ao precipitar o 
processo imune, apesar de não haver, até agora, uma relação causal estabelecida entre estes 
dois fatores e a síndrome. As infeções mais frequentemente associadas originam-se no tracto 
respiratório, e têm como agentes principais EBV, Chlamydia trachomatis, Mycoplasma 
tuberculosis, Toxoplasma gondii, e VZV. Relativamente aos fármacos, os anti-inflamatórios 
não esteroides (AINEs) e os antibióticos são os principais grupos envolvidos. 
A fisiopatologia da síndrome TINU continua por ser esclarecida. A proposta actual estima 
que um fator ambiental possa suscitar uma cascata autoimune num indivíduo com o fundo 
genético suscetível. A imunidade celular tem sido implicada como mecanismo de doença, 
principalmente através dos HLA-classe II, que exibem um papel crucial numa fase precoce 
da resposta imune, apresentando os antigénios exógenos processados a células T CD4+. 
Assim, um determinado subtipo de HLA-classe II poderia modificar a resposta imune para 
um patogénio, tornando um sujeito suscetível a um antigénio normalmente inofensivo. Para 
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além disto, a histopatologia renal evidencia infiltrados tubolointersticiais de subtipos de 
células T helper/inducer, indicando que a imunidade mediada por células T poderá ter um 
papel importante neste processo. A imunidade humoral também tem sido implicada na 
patologia da síndrome, nomeadamente pela elevada quantidade de anticorpos séricos contra 
a proteína C-modificada (anti-mCRP) em doentes com TINU, relativamente com outras 
doenças autoimunes renais e indivíduos saudáveis. Além disto, foi determinado que, em 
doentes com nefrite intersticial aguda, um título elevado de anticorpos anti-mCRP pode ser 
preditivo do desenvolvimento posterior de uveíte. Isto está de acordo com a proposta que 
sugere que o rim poderá ser o alvo primordial de um processo sequencial, que possivelmente 
levará a uma cascada inflamatória com efeitos secundários no olho. 
Os sintomas renais e oculares têm, habitualmente, uma apresentação assíncrona, surgindo 
primeiramente a nefrite intersticial e, posteriormente, a uveíte, num intervalo médio de 3 
meses. A nefrite tubulointersticial é uma causa frequente de lesão renal aguda e uma 
condição possivelmente letal. Na síndrome TINU, o envolvimento renal é geralmente 
moderado, e os doentes podem apresentar-se assintomáticos ou com uma clínica inespecífica 
de sintomas constitucionais semelhantes a um quadro gripal como febre, perda ponderal, 
artralgia e dor abdominal. A uveíte poderá ser assintomática até 50% dos doentes com TINU, 
particularmente em crianças. Caracteristicamente, esta é anterior, bilateral, de início súbito 
e não granulomatosa, tendo como sintomas habituais olho vermelho, dor e fotofobia. Como 
sinais, destacam-se a presença de hiperémia conjuntival e perilímbica e miose sem reação à 
luz. As manifestações oculares poderão ser variadas, pelo que o exame oftalmológico 
integral não deve ser dispensado. O exame à lâmpada de fenda revela caracteristicamente 
células na câmara anterior e flare, finos precipitados queráticos e células vítreas. Apesar de 
raro, o envolvimento posterior é possível e estão descritos vasculopatia com hemorragias, 
enfartes algodonosos, edema macular e do disco, coroidite e neovascularização coroideia. 
A síndrome TINU é um diagnóstico de exclusão, que normalmente é realizado ou num 
contexto de uma azotémia de origem desconhecida ou num espectro de sintomas 
oftalmológicos, como diminuição da acuidade visual, olho vermelho ou dor ocular. A 
investigação laboratorial poderá apresentar anomalias subsequentes da síndrome 
inflamatória sistémica, como uma anemia normocítica normocrómica, velocidade de 
sedimentação elevada, hipergamaglobulinémia e elevação da proteína C reactiva. Pela 
patologia intersticial renal, o exame sedimentar da urina pode demonstrar uma proteinúria 
nefrótica, hematúria microscópica, piúria estéril e aminacidúria. Biomarcadores de dano 
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tubular renal, como a N-acetilglucosaminidase (NAG) e a β2-Microglobulina (B2M) 
poderão ser úteis na suspeita do diagnóstico e são comummente encontrados na TINU. A 
B2M urinária demonstrou ter elevados valores preditivos negativos e positivos na deteção 
da doença renal em doentes com uveíte, e tem sido proposta como um método de rastreio 
em indivíduos com uveíte. 
A biópsia renal é o único exame que permite assegurar o diagnóstico de TINU. 
Histologicamente, caracteriza-se por edema intersticial com células inflamatórias e dano 
tubular com edema tubular, degeneração epitelial e necrose focal. Pelo facto de ser um exame 
invasivo, a realização da biópsia renal deverá ser ponderada caso a caso. 
O diagnóstico diferencial realiza-se com doenças com manifestações oculo-renais, como 
a sarcoidose, o lúpus eritematoso sistémico, poliangeíte granulomatosa, tuberculose e sífilis. 
As características da uveíte, a idade de início e outros sinais e sintomas sistémicos 
específicos podem prontamente distinguir estas patologias. Uma revisão de sintomas 
completa e um exame clínico devem guiar os testes serológicos e imagiológicos posteriores. 
Os critérios de diagnóstico da síndrome TINU foram descritos por Mandeville em 2001, e 
incluem a uveíte característica, alterações da função renal, alterações das análises urinárias, 
sinais e sintomas de doença sistémica e achados laboratoriais de síndrome inflamatório. 
Pelo facto de as doenças renal e ocular poderem ser assíncronas e/ou assintomáticas, 
admite-se que a TINU seja uma síndrome sub-diagnosticada, fazendo possivelmente parte 
dos diagnósticos incorretamente estabelecidos de nefrite intersticial idiopática e uveíte 
anterior idiopática, especialmente numa faixa etária mais jovem.  
O seguimento a longo prazo da TINU continua não totalmente conhecido e o tratamento 
não suficientemente bem estudado. Apesar de o prognóstico ser geralmente bom para ambos 
os órgãos, a doença renal e a doença ocular parecem ter cursos e severidades independentes, 
com a uveíte tendencialmente a ser de um controlo mais complexo e a doença renal 
frequentemente auto-limitada. Na uveíte anterior no contexto de TINU, o tratamento com 
corticoide tópico exclusivo não é suficiente em 80% dos doentes, muitas vezes sendo 
necessário corticoterapia sistémica. Após suspensão do tratamento sistémico, a uveíte tende 
a recorrer em 50% dos doentes, sendo as recidivas normalmente mais graves que o evento 
inicial. Os fármacos imunomoduladores são o tratamento de segunda-linha, e incluem o 
metotrexato, a ciclosporina, azatioprina e o micofenolato de mofetil. Este tratamento pode 
ser considerado em casos resistentes aos corticosteroides e para evitar os efeitos adversos 
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relacionados com os corticoides. As complicações oculares ocorrem em 20% dos doentes e 
incluem sinéquias posterior, edema do disco óptico, edema macular cistoide e cataratas.  
A doença renal pode igualmente requerer terapêutica sistémica com corticosteroides, já 
que mesmo danos teciduais mínimos podem levar a doença renal crónica e hipertensão.  
O curso e a severidade da TINU e do seu tratamento devem ser geridos em conjunto por 
oftalmologistas e nefrologistas. No que respeita o seguimento, é recomendado a realização 
de análises urinárias e quantificação da excreção urinária de proteínas de baixo peso 
molecular. O rastreio oftalmológico é também aconselhado a todos os doentes com nefrite 
tubulointerstecial isolada, até um ano depois do diagnóstico.  
No caso clínico 1, uma doente de 18 anos recorreu a cuidados médicos por alteração do 
estado geral com cansaço progressivo, náusea, vómitos e perda de peso durante várias 
semanas. Laboratorialmente, determinou-se uma elevação da creatinina sérica (2.8 mg/dL) 
e da velocidade de sedimentação (90 mm/h), com uma proteinúria de 400 mg/24h. A doente 
não apresentava quaisquer sintomas reumáticos e a serologias viral e estudo de auto-
imunidade foram negativos. Os exames de imagem e os níveis de enzima conversora da 
angiotensina revelaram-se também normais. Um mês mais tarde, surgiram sintomas 
oftalmológicos com dor ocular e diminuição da acuidade visual, e o diagnóstico de uveíte 
anterior foi estabelecido. Verificou-se refractariedade ao tratamento inicial com 
prednisolona oral, com múltiplas recidivas da inflamação ocular, pelo que um tratamento 
com metotrexato oral foi iniciado, com boa tolerância e sem recorrência de sintomas sob 1 
ano de tratamento. 
No caso clínico 2, uma criança de 12 anos apresentou-se com vermelhidão ocular e 
fotofobia. O exame oftalmológico à lampa de fenda mostrou finos precipitados queráticos e 
sinéquia posterior, pelo que o diagnóstico de uveíte anterior aguda não granulomatosa foi 
determinado. Em avaliação analítica realizada 1 mês antes, uma anemia normocítica 
normocrómica teria sido diagnosticada. Após exclusão de outros diagnósticos, a biópsia 
renal permitiu estabelecer o diagnóstico de TINU. Tal como no caso anterior, foi iniciado 
tratamento com com metotrexato, com regressão da inflamação ocular e sem outras 
complicações adicionais. 
Os casos clínicos apresentados refletem a ampla gama de sintomas que os pacientes com 
TINU podem manifestar e destacam a complexidade deste diagnóstico. Ambos os pacientes 
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apresentaram cursos típicos de doença olho-rim e a resposta ao tratamento foi semelhante à 
anteriormente relatada na literatura e detalhada nesta revisão. É importante ter em mente o 
sub-reconhecimento da síndrome TINU, pois sua prevalência e importância podem ser muito 
mais elevadas do que inicialmente se sabia. Um alto ídice de suspeição é fundamental, 
especialmente nos casos interpretados como nefrite tubulointersticial idiopática ou uveíte 
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